Das S K, Das N G
Nova Southeastern University, College of Pharmacy, Ft. Lauderdale, FL 33328, USA.
J Microencapsul. 1998 Jul-Aug;15(4):445-52. doi: 10.3109/02652049809006871.
A microparticulate dosage form for a highly soluble drug, diltiazem hydrochloride, was formulated with Eudragit RS100 and RL100 using a novel dual polymer technique. A mixture of diltiazem with Eudragit RS100 (low water permeability) in acetone was coacervated into soft polymer microdrops, following which a mixture of diltiazem and RL100 (high water permeability) was added to produce microparticles consisting of both polymers with diltiazem dispersed in the matrix. A second formulation was developed using the same method except using Eudragit RS100 for both steps. For a comparative study, diltiazem, Eudragit RS100 and RL100 were combined together in a single matrix and formulated into microparticles. In vitro drug release profiles using USP paddle dissolution apparatus 2 revealed that dual polymer matrix microparticles containing Eudragit RS100 in the inner and Eudragit RL100 in the outer core exhibit a suitable release profile with an initial release of the drug followed by a plateau level for the test period of 5 h. Differential scanning calorimetric analysis showed no interaction of the drug with the polymers.
采用新型双聚合物技术,用丙烯酸树脂RS100和RL100制备了高溶解性药物盐酸地尔硫䓬的微粒剂型。将地尔硫䓬与丙烯酸树脂RS100(低水渗透性)在丙酮中的混合物凝聚成柔软的聚合物微滴,随后加入地尔硫䓬与RL100(高水渗透性)的混合物,制得由两种聚合物组成且地尔硫䓬分散在基质中的微粒。采用相同方法开发了第二种制剂,但两步均使用丙烯酸树脂RS100。为进行对比研究,将地尔硫䓬、丙烯酸树脂RS100和RL100在单一基质中混合并制成微粒。使用美国药典桨法溶出装置2进行的体外药物释放曲线显示,内芯含丙烯酸树脂RS100、外芯含丙烯酸树脂RL100的双聚合物基质微粒呈现出合适的释放曲线,药物在5小时的测试期内先有初始释放,随后达到平稳水平。差示扫描量热分析表明药物与聚合物之间没有相互作用。